A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: procedure (650), etiquette (1), practice (609)

UHS adult major trauma guidelines

Description
Adult Major Trauma Guidelines University Hospital Southampton NHS Foundation Trust Dr Mark Baxter Director of Major Trauma, Consultant in Older Persons Medicine Prof Rob Crouch Deputy Director of Major Trauma, Consultant Nurse in Emergency Medicine Emma Bowyer Major Trauma Centre and Wessex Trauma Network Manager Amendment’s log No. Amendments 1. Update Wessex Trauma Network Automatic acceptance tool 2. Hyperlinks added from contents page Page No. 22 4 3.
Url
/Media/SUHTExtranet/WessexTraumaNetwork/UHS-adult-major-trauma-guidelines.pdf

Papers CoG 28.10.2025

Description
Date Time Location Chair Agenda - Council of Governors 28/10/2025 14:00 - 15:30 Heartbeat Conference Room/Microsoft Teams Jenni Douglas-Todd 1 Chair’s Welco
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-28.10.2025.pdf

Daratumumab

Description
Chemotherapy Protocol Myeloma Daratumumab Regimen • Myeloma – Daratumumab monotherapy Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and refractory
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab.pdf

AmB-(TICE)-Carboplatin-Etoposide

Description
Chemotherapy Protocol GERM CELL Amb TICE (Part 2): Carboplatin – Etoposide phosphate Ambulatory Regimen This regimen is for AMBULATORY CARE pathway
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/AmB-TICE-Carboplatin-Etoposide.pdf

Annual report 20-21

Description
2020/21 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2020/21 Presented to Parliament
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-20-21.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone Cycles 1 to 8

Description
Chemotherapy Protocol Myeloma DVd (Weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 1 to 8) Regimen • Myeloma – Bortezomib (weekly)-Daratumumab-Dexamethasone Indication • Daratumumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-Cycles-1-to-8.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

VR-RituximabVenetoclax Cycle_2 Onwards

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) (Cycle 2 onwards) Regimen • CLL – VR Rituximab Venetoclax (high risk) Cycle
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclax-Cycle-2-Onwards.pdf

CH003 regimen validation checklist ver2.0x

Description
Central South Coast Cancer Network Strength through Partnership Checklist for Verification of Treatment Regimens in ARIA Ver
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Validation/CH003regimenvalidationchecklistver20x.pdf

DVd Weekly Daratumumab-Bortezomib-Dexamethasone weekly Cycles 9 onwards

Description
Chemotherapy Protocol Myeloma DVd (weekly) Bortezomib-Daratumumab-Dexamethasone (cycles 9 onwards) Regimen • Myeloma – Bortezomib (weekly) with daratumumab and dexamethasone Indication • Daratumumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-Weekly-Daratumumab-Bortezomib-Dexamethasone-weekly-Cycles-9-onwards.pdf
51 to 60 of 698
Previous … 4 5 6 7 8 … Next